Samyshkin, Yevgeniy; Kotchie, Robert; Mörk, Ann-Christin; … - In: The European Journal of Health Economics 15 (2014) 1, pp. 69-82
The addition of roflumilast to LABA in the treatment of patients with severe-to-very severe COPD reduces the rate of exacerbations and can be cost-effective in the UK setting. </AbstractSection> Copyright The Author(s) 2014